EyePoint Pharmaceuticals (XTER:PV3) 5-Year EBITDA Growth Rate : 27.70% (As of Dec. 2023)

View and export this data going back to 2008. Start your Free Trial

What is EyePoint Pharmaceuticals 5-Year EBITDA Growth Rate?

EyePoint Pharmaceuticals's EBITDA per Share for the three months ended in Dec. 2023 was €-0.36.

During the past 3 years, the average EBITDA Per Share Growth Rate was 13.80% per year. During the past 5 years, the average EBITDA Per Share Growth Rate was 27.70% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.

During the past 13 years, the highest 3-Year average EBITDA Per Share Growth Rate of EyePoint Pharmaceuticals was 92.00% per year. The lowest was -844.50% per year. And the median was -2.70% per year.

Competitive Comparison of EyePoint Pharmaceuticals's 5-Year EBITDA Growth Rate

For the Biotechnology subindustry, EyePoint Pharmaceuticals's 5-Year EBITDA Growth Rate, along with its competitors' market caps and 5-Year EBITDA Growth Rate data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

EyePoint Pharmaceuticals's 5-Year EBITDA Growth Rate Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, EyePoint Pharmaceuticals's 5-Year EBITDA Growth Rate distribution charts can be found below:

* The bar in red indicates where EyePoint Pharmaceuticals's 5-Year EBITDA Growth Rate falls into.

EyePoint Pharmaceuticals 5-Year EBITDA Growth Rate Calculation

This is the 5-year average growth rate of EBITDA per Share. The growth rate is calculated with least square regression.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.

EyePoint Pharmaceuticals (XTER:PV3) 5-Year EBITDA Growth Rate Explanation

EBITDA per Share is the amount of Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) per outstanding share of the company's stock.

Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.

5-Year EBITDA Growth Rate gives an overview of the company's growth in operating profitability and is an important factor used in calculating Peter Lynch Fair Value.

EyePoint Pharmaceuticals 5-Year EBITDA Growth Rate Related Terms

Thank you for viewing the detailed overview of EyePoint Pharmaceuticals's 5-Year EBITDA Growth Rate provided by GuruFocus.com. Please click on the following links to see related term pages.

EyePoint Pharmaceuticals (XTER:PV3) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » EyePoint Pharmaceuticals Inc (XTER:PV3) » Definitions » 5-Year EBITDA Growth Rate

Comparable Companies

Traded in Other Exchanges

EYPT:USA PV3B:Germany

Address

480 Pleasant Street, Suite B300, Watertown, MA, USA, 02472

Website

https://www.eyepointpharma.com

EyePoint Pharmaceuticals Inc is a pharmaceutical company. It is engaged in developing and commercializing ophthalmic products for the treatment of eye diseases. The company has developed FDA-approved sustained-release treatments in ophthalmology. Its pre-clinical development program is focused on using its core Durasert and Verisome technology platforms to deliver drugs to treat wet age-related macular degeneration, glaucoma, osteoarthritis, and other diseases. Geographically, the firm has operational footprints in the U.S., China, and the UK. It generates a majority of its revenue from the U.S.

EyePoint Pharmaceuticals (XTER:PV3) Headlines

No Headlines